全文获取类型
收费全文 | 1673篇 |
免费 | 101篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 36篇 |
妇产科学 | 76篇 |
基础医学 | 182篇 |
口腔科学 | 31篇 |
临床医学 | 141篇 |
内科学 | 471篇 |
皮肤病学 | 26篇 |
神经病学 | 170篇 |
特种医学 | 48篇 |
外科学 | 146篇 |
综合类 | 5篇 |
预防医学 | 88篇 |
眼科学 | 16篇 |
药学 | 197篇 |
中国医学 | 7篇 |
肿瘤学 | 141篇 |
出版年
2024年 | 1篇 |
2023年 | 15篇 |
2022年 | 30篇 |
2021年 | 56篇 |
2020年 | 32篇 |
2019年 | 47篇 |
2018年 | 54篇 |
2017年 | 43篇 |
2016年 | 51篇 |
2015年 | 68篇 |
2014年 | 72篇 |
2013年 | 85篇 |
2012年 | 139篇 |
2011年 | 136篇 |
2010年 | 69篇 |
2009年 | 55篇 |
2008年 | 95篇 |
2007年 | 108篇 |
2006年 | 100篇 |
2005年 | 111篇 |
2004年 | 78篇 |
2003年 | 99篇 |
2002年 | 79篇 |
2001年 | 20篇 |
2000年 | 19篇 |
1999年 | 19篇 |
1998年 | 18篇 |
1997年 | 5篇 |
1996年 | 10篇 |
1995年 | 9篇 |
1994年 | 4篇 |
1993年 | 4篇 |
1992年 | 11篇 |
1991年 | 8篇 |
1990年 | 4篇 |
1989年 | 3篇 |
1988年 | 7篇 |
1987年 | 7篇 |
1986年 | 5篇 |
1985年 | 5篇 |
1984年 | 3篇 |
1983年 | 4篇 |
1964年 | 1篇 |
排序方式: 共有1789条查询结果,搜索用时 31 毫秒
81.
Falzone Yuri Matteo Domi Teuta Agosta Federica Pozzi Laura Schito Paride Fazio Raffaella Del Carro Ubaldo Barbieri Alessandra Comola Mauro Leocani Letizia Comi Giancarlo Carrera Paola Filippi Massimo Quattrini Angelo Riva Nilo 《Journal of neurology》2020,267(8):2272-2280
Journal of Neurology - To investigate the prognostic role and the major determinants of serum phosphorylated neurofilament heavy -chain (pNfH) concentration across a large cohort of motor neuron... 相似文献
82.
Arturo Ciccullo Gianmaria Baldin Vanni Borghi Filippo Lagi Alessandra Latini Gabriella dEttorre Letizia Oreni Paolo Fusco Amedeo Capetti Massimiliano Fabbiani Andrea Giacomelli Alessandro Grimaldi Giordano Madeddu Gaetana Sterrantino Cristina Mussini Simona Di Giambenedetto 《Viruses》2022,14(1)
Dolutegravir (DTG) is currently one of the most used Integrase inhibitors (INI) in antiretroviral therapies (ARV) in both naïve and experienced people living with HIV (PLWHIV). We analyzed a multicenter cohort of PLWHIV, both naïve and experienced, starting an ARV including DTG. We enrolled 3775 PLWHIV: 2763 (73.2%) were males, with a median age of 50 years. During 9890.7 PYFU, we observed 930 discontinuations (9.4 per 100 PYFU). Estimated probabilities of maintaining DTG at three and five years were 75.1% and 67.2%, respectively. Treatment-naïve pts showed a lower probability of maintaining DTG at three and five years compared to treatment-experienced PLWHIV (log-rank p < 0.001). At a multivariate analysis, a longer time of virological suppression (aHR 0.994, p < 0.001) and having experienced a previous virological failure (aHR 0.788, p = 0.016) resulted protective against DTG discontinuation. Most discontinuations (84.0%) happened within the first 12 months of DTG initiation, in particular, 92.2% of discontinuations due to neuropsychiatric toxicity were observed in the first year. Our data confirm the overall good tolerability of DTG in clinical practice, with a low rate of discontinuations. CNS toxicity resulted the main reason for DTG discontinuation, with most related interruptions happening in the first year from DTG introduction. 相似文献
83.
Federico Pappalardo Evgenij Potapov Antonio Loforte Michiel Morshuis David Schibilsky Daniel Zimpfer Julia Riebandt Christian Etz Matteo Attisani Mauro Rinaldi Assad Haneya Faiz Ramjankhan Dirk Donker Ulrich P Jorde Daniel Lewin Radi Wieloch Rafael Ayala Jochen Cremer Letizia Bertoldi Michael Borger Artur Lichtenberg Jan Gummert Diyar Saeed the Durable MCS after ECLS study group 《Interactive Cardiovascular and Thoracic Surgery》2022,34(4):676
Open in a separate window OBJECTIVESImplanting a durable left ventricular assist device (LVAD) in a patient on extracorporeal life support (ECLS) is challenging. The goal of this study was to compare the results of patients from a European registry who had a durable LVAD implanted with or without transition from ECLS to cardiopulmonary bypass (CPB).METHODSA total of 531 patients on ECLS support who had an LVAD implant between January 2010 and August 2018 were analysed; after 1:1 propensity score matching, we identified and compared 175 patients in each group.RESULTSThe duration of preoperative ECLS was 7 [standard deviation (SD) 6] vs 7 (SD 6) days in patients with or without CPB (P = 0.984). The surgical time was longer in the CPB group [285 (SD 72) vs 209 [SD 75] min; P ≤ 0.001). The postoperative chest tube output was comparable [1513 (SD 1311) vs 1390 (SD 1121) ml; P = 0.3]. However, re-exploration for bleeding was necessary in 41% vs 29% of patients with or without CPB (P = 0.01) and a significantly higher number of packed red blood cells and fresh frozen plasma [8 (SD 8) vs 6 (SD 4) units; P = 0.001 and 6 (SD 7) vs 5 (SD 5) units; P = 0.03] were administered to patients operated on with CPB. A postoperative mechanical right ventricular support device was necessary in 50% vs 41% of patients (P = 0.08). The stroke rate was not significantly different (P 0.99). No difference in survival was observed.CONCLUSIONSOmitting CPB for an LVAD implant in patients on ECLS is safe and results in shorter operating time, less re-exploration for bleeding and fewer blood products. However, no survival benefit is observed. 相似文献
84.
85.
86.
Nicola Parenti Maria Letizia Bacchi Reggiani Primiano Iannone Daniela Percudani Dawn Dowding 《International journal of nursing studies》2014
Objective
To conduct a systematic review to check the level of validity and reliability of the Manchester Triage System and the quality of reporting of literature on this topic.Design
This is a systematic review based on the PRISMA guideline on reporting systematic reviews.Data sources
The systematic search of the international literature published from 1997 through 30 November 2012 in the PubMed, Embase, Cochrane Library, Cinahl, Web of Knowledge, and Scopus databases.Review methods
This review included quantitative and qualitative research investigating the reliability and validity of the Manchester Triage System for the broad population of adults and children visiting the emergency department.After a systematic selection process, included studies were assessed on their quality by three researchers using the STARD guidelines.Results
Twelve studies were included in the review. The studies investigated the inter- and intra-rater reliability using the “kappa” statistic; the validity was tested with many measures: validity in predicting mortality, hospital admission, under- and overtriage, used resources, and length of stay in the emergency department, as well as a reference standard rating.Conclusions
In this review, the Manchester Triage System shows a wide inter-rater agreement range with a prevalence of good and very good agreement. Its safety was low because of the high rate of undertriage and the low sensitivity in predicting higher urgency levels. The high rate of overtriage could cause unnecessarily high use of resources in the emergency department. The quality of the reporting in studies of the reliability and validity of the Manchester Triage System is good. 相似文献87.
88.
Cardiac resynchronization therapy: variations in echo-guided optimized atrioventricular and interventricular delays during follow-up 总被引:1,自引:0,他引:1
Valzania C Biffi M Martignani C Diemberger I Bertini M Ziacchi M Bacchi L Rocchi G Rapezzi C Branzi A Boriani G 《Echocardiography (Mount Kisco, N.Y.)》2007,24(9):933-939
BACKGROUND: Relatively few data are available on long-term echocardiographic optimization of atrioventricular (AV) and interventricular (VV) delay programming in cardiac resynchronization therapy (CRT). We assessed variations in optimized AV and VV delays during long-term follow-up. METHODS: Thirty-seven consecutive heart failure patients received Doppler echocardiographic optimization of AV and VV delay within 48 hours from CRT device implantation, at 6 months and at 12 months (the last for the first enrolled 14 patients). RESULTS: After implantation, median optimized AV delay was 100 ms (range, 45 ms); VV optimization led to simultaneous biventricular activation in 4 patients, left ventricular preactivation in 17 patients and right ventricular preactivation in 16 patients. At 12 months median AV delay decreased to 85 ms (23 ms) (P < 0.05 vs. baseline). With respect to previous assessment, VV delay variations > or =40 ms were observed in 41% of the patients at 6 months and in 57% of the tested patients at 12 months. A nonconcordance (by Kappa test) of optimized VV delays was found between each new assessment and the previous one. VV delay optimization was associated with significant (P < 0.001) increases in aortic velocity time integral both at baseline and during follow-up. CONCLUSIONS: Echocardiographic optimization of AV and VV delay is associated with broad intraindividual variability during follow-up. A new assessment of optimized VV delays during long-term follow-up reveals a nonconcordance with previous values and provides increases in forward stroke volume. 相似文献
89.
Arca M Montali A Pigna G Antonini R Antonini TM Luigi P Fraioli A Mastrantoni M Maddaloni M Letizia C 《Metabolism: clinical and experimental》2007,56(11):1534-1541
Statins and fibrates have different effects on lipid abnormalities of familial combined hyperlipidemia (FCHL); thus, the selection of the first-line drug is troublesome. We evaluated to what extent monotherapy with a potent statin is more effective than fibrate in reaching the recommended lipid targets in FCHL. Fifty-six patients were randomized to receive optimal dosage of atorvastatin (n = 27) or 200 mg/d micronized fenofibrate (n = 29) for 24 weeks. To reach the optimal dosage, atorvastatin was up-titrated at each follow-up visit if low-density lipoprotein (LDL) cholesterol >130 mg/dL (>100 mg/dL in patients with coronary or cerebrovascular disease). The effects of fenofibrate and atorvastatin on lipoprotein fractions as well as on plasma levels of endothelin-1 (ET-1) and adrenomedullin (AM) were also evaluated. At end of trial, a greater proportion of patients on atorvastatin (average dosage, 20.8 mg/d) reached lipid targets in comparison with those on fenofibrate (64% vs 32.1%, P = .02). Atorvastatin was significantly more effective in reducing total cholesterol, LDL cholesterol, apolipoprotein B, and non-high-density lipoprotein (HDL) cholesterol. Conversely, triglycerides decreased and HDL increased more during fenofibrate. Nevertheless, atorvastatin produced a marked reduction in very low-density lipoprotein and very low-density lipoprotein remnants. Atorvastatin lowered all LDL subtypes, although fenofibrate appeared to be more effective on denser LDL. Compared with 43 normolipemic controls, FCHL patients presented increased baseline plasma levels of ET-1 (P = .007) but not of AM. Fenofibrate, but not atorvastatin, significantly lowered ET-1 levels by 16.7% (P < .05). Neither drug significantly affected plasma concentrations of AM. In summary, although fenofibrate showed superiority in raising HDL and reducing ET-1, atorvastatin was more effective in reaching lipid targets in FCHL so that it can be proposed as the first-line option in the management of this atherogenic hyperlipidemia. 相似文献
90.
Federico Boscari Martina Vettoretti Anna Maria Letizia Amato Valeria Vallone Ambra Uliana Elisabetta Iori Angelo Avogaro Andrea Facchinetti Daniela Bruttomesso 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2021,31(2):650-657
Background and aimsContinuous glucose monitoring improves glycemic control in diabetes. This study compared the accuracy of the Dexcom G5 Mobile (Dexcom, San Diego, CA) transcutaneous sensor (DG5) and the first version of Eversense (Senseonics,Inc., Germantown, MD) implantable sensor (EVS).Methods and resultsSubjects with type 1 diabetes (T1D) and using EVS wore simultaneously DG5 for seven days. At day 3, patients were admitted to a clinical research center (CRC) to receive breakfast with delayed and increased insulin bolus to induce glucose excursions. At CRC, venous glucose was monitored every 15 min (or 5 min during hypoglycemia) for 6 h by YSI 2300 STAT PLUS? glucose and lactate analyzer. At home patients were requested to perform 4 fingerstick glucose measurements per day.Eleven patients (9 males, age 47.4 ± 11.3 years, M±SD) were enrolled. During home-stay the median [25th-75th percentile] absolute relative difference (ARD) over all CGM-fingerstick matched-pairs was 11.64% [5.38–20.65]% for the DG5 and 10.75% [5.15–19.74]% for the EVS (p-value = 0.58). At CRC, considering all the CGM-YSI matched-pairs, the DG5 showed overall smaller median ARD than EVS, 7.91% [4.14–14.30]% vs 11.4% [5.04–18.54]% (p-value<0.001). Considering accuracy during blood glucose swings, DG5 performed better than EVS when glucose rate-of-change was ?0.5 to ?1.5 mg/dL/min, with median ARD of 7.34% [3.71–12.76]% vs 13.59% [4.53–20.78]% (p-value<0.001), and for rate-of-change < -1.5 mg/dl/min, with median ARD of 5.23% [2.09–15.29]% vs 12.73% [4.14–20.82]% (p-value = 0.02).ConclusionsDG5 was more accurate than EVS at CRC, especially when glucose decreased. No differences were found at home. 相似文献